Triple Therapy With Ribavirin, Sofosbuvir, And Daclatasvir Increases SVR Achievement In Patients With HCV Complicated By Cirrhosis, Study Finds

August 17, 2022

Infectious Disease Advisor (8/16, Paridon) reports “triple therapy with ribavirin plus sofosbuvir and daclatasvir increases the rate [of] sustained virologic response (SVR) achievement in patients with hepatitis C virus (HCV) infection complicated by cirr...